REALIST-COVID-19:间充质基质细胞治疗COVID-19相关ARDS的三盲随机对照试验方案摘要
REALIST-COVID-19是一项随机、安慰剂对照、三盲试验,评估单次静脉输注CD362富集人脐带来源间充质基质细胞(MSCs)在COVID-19所致中重度ARDS患者中的安全性,主要安全结局为严重不良事件发生率,主要疗效结局为第7天氧合指数,计划随机60例(1:1),截至发表已入组12例。
要点
- 单次静脉输注400×10^6个CD362富集脐带MSCs,对照为200ml Plasma-Lyte 148。
- 主要安全结局为严重不良事件发生率,主要疗效结局为第7天氧合指数。
- 纳入需有创机械通气且符合柏林定义的中重度ARDS、COVID-19诊断,ARDS起病≤72小时。
核心结论
- 该研究旨在评估单次静脉输注CD362富集人脐带来源MSCs在COVID-19相关ARDS患者中的安全性,并观察其对重要临床结局的影响。
研究设计与样本
- 随机、安慰剂对照、三盲试验,在英国多个ICU开展,计划随机60例(干预组30例、对照组30例),按中心和血管加压药使用分层,1:1分配。
- 纳入标准为柏林定义的中重度ARDS、接受有创机械通气、临床诊断或PCR确诊COVID-19;排除ARDS起病超过72小时、年龄<16岁等。
- 干预为单次静脉输注400×10^6个CD362富集人脐带来源MSCs(REALIST ORBCEL-C),对照为200ml Plasma-Lyte 148。
主要发现
- 原文为方案摘要,未报告试验结果;截至发表,5个中心开放入组,已入组12例患者。
关键数值与推荐
- 主要安全结局为严重不良事件发生率;主要疗效结局为第7天氧合指数(OI)。
- 次要结局包括第4、14天OI,第4、7、14天呼吸顺应性、驱动压和PaO2/FiO2比值,第4、7、14天SOFA评分,拔管与再插管,第28天无通气天数,机械通气时长,ICU和住院时长,28天和90天死亡率。
- 样本量计划60例,若可行将继续入组超过60例以获得更准确结果,总入组数取决于疫情并由数据监测与伦理委员会指导。
临床怎么用
- 该方案用于评估MSCs在COVID-19相关ARDS中的安全性和临床结局,结果尚未报告,暂不能指导临床实践。
局限性
- 本文为研究方案摘要,无结果数据;样本量较小(计划60例),入组受疫情影响,可能影响结论的确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The primary objective of the study is to assess the safety of a single intravenous infusion of Mesenchymal Stromal Cells (MSCs) in patients with Acute Respiratory Distress Syndrome (ARDS) due to COVID-19. Secondary objectives are to determine the effects of MSCs on important clinical outcomes, as described below. TRIAL DESIGN: REALIST COVID 19 is a randomised, placebo-controlled, triple blinded trial. PARTICIPANTS: The study will be conducted in Intensive Care Units in hospitals across the United Kingdom. Patients with moderate to severe ARDS as defined by the Berlin definition, receiving invasive mechanical ventilation and with a diagnosis of COVID-19 based on clinical diagnosis or PCR test will be eligible. Patients will be excluded for the following reasons: more than 72 hours from the onset of ARDS; age < 16 years; patient known to be pregnant; major trauma in previous 5 days; presence of any active malignancy (other than non-melanoma skin cancer); WHO Class III or IV pulmonary hypertension; venous thromboembolism currently receiving anti-coagulation or within the past 3 months; patient receiving extracorporeal life support; severe chronic liver disease (Child-Pugh > 12); Do Not Attempt Resuscitation order in place; treatment withdrawal imminent within 24 hours; prisoners; declined consent; non-English speaking patients or those who do not adequately understand verbal or written information unless an interpreter is available; previously enrolled in the REALIST trial. INTERVENTION AND COMPARATOR: Intervention: Allogeneic donor CD362 enriched human umbilical cord derived mesenchymal stromal cells (REALIST ORBCEL-C) supplied as sterile, single-use cryopreserved cell suspension of a fixed dose of 400 x106 cells in 40ml volume, to be diluted in Plasma-Lyte 148 to a total volume of 200mls for administration. Comparator (placebo): Plasma-Lyte 148 Solution for Infusion (200mls). The cellular product (REALIST ORBCEL-C) was developed and patented by Orbsen Therapeutics. MAIN OUTCOMES: The primary safety outcome is the incidence of serious adverse events. The primary efficacy outcome is Oxygenation Index (OI) at day 7. Secondary outcomes include: OI at days 4 and 14; respiratory compliance, driving pressure and PaO2/FiO2 ratio (PF ratio) at days 4, 7 and 14; Sequential Organ Failure Assessment (SOFA) score at days 4, 7 and 14; extubation and reintubation; ventilation free days at day 28; duration of mechanical ventilation; length of ICU and hospital stay; 28-day and 90-day mortality. RANDOMISATION: After obtaining informed consent, patients will be randomised via a centralised automated 24-hour telephone or web-based randomisation system (CHaRT, Centre for Healthcare Randomised Trials, University of Aberdeen). Randomisation will be stratified by recruitment centre and by vasopressor use and patients will be allocated to REALIST ORBCEL-C or placebo control in a 1:1 ratio. BLINDING (MASKING): The investigator, treating physician, other members of the site research team and participants will be blinded. The cell therapy facility and clinical trials pharmacist will be unblinded to facilitate intervention and placebo preparation. The unblinded individuals will keep the treatment information confidential. The infusion bag will be masked at the time of preparation and will be administered via a masked infusion set. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A sample size of 60 patients with 30 patients randomised to the intervention and 30 to the control group. If possible, recruitment will continue beyond 60 patients to provide more accurate and definitive trial results. The total number of patients recruited will depend on the pandemic and be guided by the data monitoring and ethics committee (DMEC). TRIAL STATUS: REALIST Phase 1 completed in January 2020 prior to the COVID-19 pandemic. This was an open label dose escalation study of REALIST ORBCEL-C in patients with ARDS. The COVID-19 pandemic emerged as REALIST Phase 2 was planned to commence and the investigator team decided to repurpose the Phase 2 trial as a COVID-19 specific trial. This decision was discussed and approved by the Trial Steering Committee (TSC) and DMEC. Submissions were made to the Research Ethics Committee (REC) and MHRA to amend the protocol to a COVID-19 specific patient population and the protocol amendment was accepted by the REC on 27th March 2020 and MHRA on 30th March 2020 respectively. Other protocol changes in this amendment included an increase in the time of onset of ARDS from 48 to 72 hours, inclusion of clinical outcomes as secondary outcomes, the provision of an option for telephone consent, an indicative sample size and provision to continue recruitment beyond this indicative sample size. The current protocol in use is version 4.0 23.03.2020 (Additional file 1). Urgent Public Health status was awarded by the NIHR on 2 April 2020 and the trial opened to recruitment and recruited the first participant the same day. At the time of publication the trial was open to recruitment at 5 sites across the UK (Belfast Health and Social Care Trust, King's College London, Guys and St Thomas' Hospital London, Birmingham Heartlands Hospital and the Queen Elizabeth Hospital Birmingham) and 12 patients have been recruited across these sites. Additional sites are planned to open and appropriate approvals for these are being obtained. It is estimated recruitment will continue for 6 months. TRIAL REGISTRATION: ClinicalTrials.gov NCT03042143 (Registered 3 Feb 2017). EudraCT 2017-000585-33 (Registered 28 Nov 2017). FULL PROTOCOL: The full protocol (version 4.0 23.03.2020) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
引用
- Gorman E, Shankar-Hari M, Hopkins P, et al. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. Trials. 2020. PMID: 32493473. doi:10.1186/s13063-020-04416-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。